This inventor holds 1 USPTO granted patent. Top assignees: Biology Centre as Cr, V.v.i., Institute for Clinical and Experimental Medicine, Institute of Microbiologyh as Cr, V.v.i.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3 
1 out of 1 
1 out of 1 Years Active: 2016
Title: Vaclav Kristufek: Innovator in Anti-Inflammatory Metabolites
Introduction
Vaclav Kristufek is a notable inventor based in Ceske Budejovice, Czech Republic. He has made significant contributions to the field of microbiology and biochemistry, particularly through his work on manumycin-type metabolites. His research has the potential to impact the development of anti-inflammatory agents.
Latest Patents
Kristufek holds a patent for a manumycin-type metabolite called Colabomycin E. This compound inhibits caspase 1 and the creation of interleukins. The strain that produces Colabomycin E is SOK1/5-04, which is deposited in The Czech Collection of Microorganisms under number CCM8556. Colabomycin E is structurally similar to the known metabolite colabomycin A, but it features a polyene chain that is two carbons longer. Biological activity assays have shown that Colabomycin E significantly inhibits IL-1β release from THP-1 cells, indicating its potential as an anti-inflammatory agent.
Career Highlights
Throughout his career, Vaclav Kristufek has worked at prominent institutions such as the Biology Centre and the Institute of Microbiology, both as part of the Czech Republic's research community. His work has focused on the exploration of microbial metabolites and their applications in medicine.
Collaborations
Kristufek has collaborated with notable colleagues, including Miroslav Petricek and Katerina Petrickova. Their joint efforts have contributed to advancing research in the field of microbiology and the development of new therapeutic agents.
Conclusion
Vaclav Kristufek's innovative work on Colabomycin E exemplifies the potential of microbial metabolites in medical applications. His contributions to the field continue to pave the way for future research and development in anti-inflammatory therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile